# First in Human Study of T3P-Y058-739 (T3P)

> **NCT05120596** · PHASE1,PHASE2 · RECRUITING · sponsor: **T3 Pharmaceuticals AG** · enrollment: 100 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** Pembrolizumab+T3P-Y058-739
- **DRUG:** T3P-Y058-739 (IV)
- **DRUG:** T3P-Y058-739 (IT)

## Key facts

- **NCT ID:** NCT05120596
- **Lead sponsor:** T3 Pharmaceuticals AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-04-26
- **Primary completion:** 2027-02-28
- **Final completion:** 2027-10-15
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05120596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05120596, "First in Human Study of T3P-Y058-739 (T3P)". Retrieved via AI Analytics 2026-07-31 from https://api.ai-analytics.org/clinical/NCT05120596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*